Ionis Pharmaceuticals, Inc.

IONS Healthcare Biotechnology

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue
−40.7%
EPS
−188.5%
Free cash flow
+299.3%
Total debt
+116.0%

Quarter to June 2026, against a year earlier

39.48 0.68 +1.75%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
2.12
Beneish M
−3.13
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 723.20 27.17 28.50 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
3 6 6 6 4 6 1 4 2 4
P/S ratio
15.36 11.88 11.93 7.53 10.82 5.29 9.08 9.61 7.41 13.41
Altman Z-Score
3.67 3.90 3.41 4.60 3.05 2.02 1.44 1.58 0.89 2.12
P/FCF ratio
0.00 44.81 12.22 27.34 0.00 367.72 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
0.53 2.09 4.25 6.16 2.65 4.20 2.28 2.22 1.80 1.12
Beneish M-Score
3.85 (3.38) (2.12) 0.08 (3.69) (2.69) (2.38) (0.61) (2.46) (3.13)
P/Operating CF
(213.31) 299.39 61.93 30.44 80.57 21.07 (26.63) 230.35 (45.01) (91.92)
P/B ratio
57.50 16.72 6.03 5.02 10.62 5.56 9.30 19.58 8.88 25.88
EV/Sales
14.96 11.07 9.53 6.01 9.52 4.21 7.72 8.27 5.98 12.46
EV/EBITDA
202.83 69.13 0.00 17.88 0.00 281.50 0.00 0.00 0.00 0.00
EV/FCF
(45.11) 41.77 9.77 21.81 (1,346.18) 292.06 (108.29) (19.41) (7.65) (36.11)
Current Ratio
5.96 4.80 7.88 9.97 3.56 9.75 7.07 5.90 8.47 3.83
Net Debt/EBITDA
(5.40) (5.04) 97.89 (4.54) 6.80 (72.92) 2.12 2.99 2.17 2.39
Debt/Equity
5.19 1.66 0.54 0.47 1.26 1.60 2.08 3.29 2.12 3.64
ROE
(40.22%) 0.15% 35.27% 19.37% (36.60%) (3.78%) (40.12%) (76.34%) (93.10%) (70.80%)
ROA
(6.49%) 0.03% 13.72% 9.43% (15.80%) (1.14%) (10.48%) (13.26%) (15.15%) (11.69%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(7.98%) 0.03% 13.29% 10.69% (25.94%) (1.25%) (13.72%) (16.17%) (18.87%) (16.35%)
Average Days of Receivables
105.79 44.69 7.77 20.49 38.14 27.88 15.87 45.31 47.72 25.55
Earnings Yield
(1.05%) 0.14% 3.68% 3.51% (5.73%) (0.66%) (5.06%) (4.84%) (8.70%) (2.98%)
Free Cash Flow Yield
(2.16%) 2.23% 8.18% 3.66% (0.07%) 0.27% (0.79%) (4.43%) (10.55%) (2.57%)
Free Cash Flow per Share
(1.02) 1.10 4.42 2.21 (0.04) 0.09 (0.28) (2.34) (3.69) (2.04)
Book value per Share
0.82 2.95 8.97 12.03 5.32 5.47 4.04 2.70 3.94 3.06
Free Cash Flow
(123.63) 136.29 585.25 309.35 (5.16) 12.90 (40.39) (335.50) (551.29) (325.67)
EV/EBIT
0.00 183.35 0.00 18.44 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026